NASDAQ:BNTC
Benitec Biopharma Inc.
Benitec Biopharma Inc. reported net income of −$45.5M in fiscal 2026. Free cash flow was −$16.6M, and the diluted share count rose 28.6%.Summary generated from Benitec Biopharma Inc.'s SEC filings. Latest annual report filed Sep 14, 2026.
Key statistics
Fiscal 2026 from SEC filings. MethodologyRevenue (FY26)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−33.2%
Debt / equityn/a
Free cash flow−$16.6M
FCF marginn/a
Share count change+28.6%
Financials
| Item | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | n/a | n/a |
| Operating income | −18 | −19 | −22 | −42 | −51 |
| Net income | −18 | −20 | −22 | −38 | −46 |
| Free cash flow | −16 | −18 | −20 | −24 | −17 |
Recent filings
- 8-KRegulation FD disclosure
Oct 5, 2026 - 8-KChange in auditor
Sep 30, 2026 - 8-KChange in auditor
Sep 24, 2026 - 10-KAnnual report for the fiscal year ended Jun 30, 2026
Sep 14, 2026 - 8-KResults of operations and financial condition
Sep 14, 2026 - 4Insider transaction report
Jun 30, 2026 - 8-KDirector or officer change
May 29, 2026 - 4Insider transaction report
May 28, 2026